Category - Pharma Industry News
Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
Award-winning content from Pharma Manufacturing
New NICE guidance supports shared decision making
Ontozry scores MHRA authorisation for focal-onset seizures
The patient perspective: what’s next for patient advocacy?
NICE backs Lilly’s Taltz for axial spondyloarthritis
CureVac’s COVID-19 vaccine misses the mark in late-stage study
Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration